Skip to content

Modest kidney function decline in people taking Truvada for PrEP supports need for monitoring

Albert Liu presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

‘On-demand’ rectal microbicide gel has reasonable tolerability and acceptability – daily less so

Ross Cranston presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

Almost-certain case of PrEP failure due to drug resistance reported at CROI 2016

Almost-certain case of PrEP failure due to drug resistance reported at CROI 2016

Long-acting PrEP injection tolerable and acceptable for male volunteers, but dose adjustment needed

Martin Markowitz presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

Tenofovir alafenamide PrEP protects monkeys from infection, but rectal and vaginal levels in humans may be too low

Gerardo Garcia Lerma presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

Bone density recovers quickly after stopping PrEP

Robert Grant presenting at CROI 2016. Image credit: www.croiwebcasts.org

Dose-finding trials of antibody-based drugs for HIV prevention will start soon

John Mascola presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

Combination nanotherapy drastically reduces the amount of HIV produced by cells in mice

Two cases of PrEP failure on solo tenofovir pose significant research questions